61
Participants
Start Date
July 20, 2021
Primary Completion Date
October 6, 2022
Study Completion Date
November 16, 2022
ACP-044 Dose A
Oral dose of ACP-044 Dose A
ACP-044 Dose B
Oral dose of ACP-044 Dose B
Placebo
Placebo
Drug Trials America, Inc., Hartsdale
Upstate Clinical Research Associates, LLC, Williamsville
Altoona Center for Clinical Research, Duncansville
Health Research of Hampton Roads, Newport News
Spectrum Medical, Inc., Danville
Drug Studies America, Marietta
Clinical Neuroscience Solutions, Inc., Jacksonville
Conquest Research, Winter Park
Clinical Neuroscience Solutions, Inc. dba CNS Healthcare, Orlando
Clinical Neuroscience Solutions, Inc., Orlando
M&M Medical Center, Miami
Precision Clinical Research,LLC, Sunrise
Clinical Research Investment, LLC, Birmingham
AOC-Research, Birmingham
Clinical Neuroscience Solutions, Inc., Memphis
Alliance for Multispecialty Research, LLC., Lexington
Hightop Medical Research Center, Cincinnati
Medisphere Medical Research Center, LLC, Evansville
Health Research Network II, LLC, Flossmoor
Affinity Health Corp., Oak Brook
Healthcare Research Network, Inc., Hazelwood
AMR Wichita West, Wichita
Clinical Investigations of Texas,LLC, Plano
Future Search Trials, Austin
Velocity Clinical Research-Boise, Meridian Hills
Arizona Research Center, Phoenix
AMR Las Vegas, Las Vegas
Velocity Clinical Research, North Hollywood, North Hollywood
BioSolutions Clinical Research Center, La Mesa
Encompass Clinical Research, Spring Valley
Artemis Headlands, LLC, San Diego
TriWest Research Associates, LLC, San Diego
Chase Medical Research, LLC, Waterbury
Bay State Clinical Trials, Watertown
Lead Sponsor
ACADIA Pharmaceuticals Inc.
INDUSTRY